Structure via PubChem · Public domain (PubChem)
Chemical data
- Formula
- C22H27FN4O2
- Molecular weight
- 398.5 g/mol
- IUPAC name
- N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
- SMILES
- CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C
- InChIKey
- WINHZLLDWRZWRT-ATVHPVEESA-N
- XLogP
- 2.6
- Polar surface area
- 77.2 Ų
- H-bond donors
- 3
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2006
- Admin. routes
- oral
- Indications
- neoplasm, bladder tumor, renal cell carcinoma, non-small cell lung carcinoma
via ChEMBL · EBI
Research
8,400 papers- Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2023
- Sunitinib-induced thrombotic microangiopathy.Journal of cancer research and therapeutics · 2016
- Sunitinib in the Treatment of Thyroid Cancer.Current medicinal chemistry · 2019
- Sunitinib.Drugs · 2006
- AIM2 promotes renal cell carcinoma progression and sunitinib resistance through FOXO3a-ACSL4 axis-regulated ferroptosis.International journal of biological sciences · 2023
via PubMed
Wikidata facts
- Subclass of
- heterocyclic compound
- Has part
- carbon
- Mass
- 398.212
- Has use
- medication
Show 10 more facts
- subject has role
- protein kinase inhibitors
- chemical formula
- C₂₂H₂₇FN₄O₂
- canonical SMILES
- CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C
- World Health Organisation international non-proprietary name
- sunitinib
- isomeric SMILES
- CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C
- Commons category
- Sunitinib
- medical condition treated
- gastrointestinal stromal tumor
- physically interacts with
- ret proto-oncogene
- stylized name
- SUNItinib
- significant drug interaction
- ketoconazole
Sources (7)
via Wikidata · CC0
Article · Italiano
Sunitinib (commercializzato come Sutent dalla Pfizer e precedentemente noto come SU11248 ) è un inibitore della tirosina chinasi (RTK) per via orale, a piccole molecole, approvato dalla FDA per il trattamento del carcinoma a cellule renali (RCC) e per il tumore stromale gastrointestinale (GIST) imatinib resistente il 26 gennaio 2006. Sunitinib è stato il primo farmaco antitumorale approvato contemporaneamente per due diverse indicazioni.
Abstract from DBpedia / Wikipedia · CC BY-SA